These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 11154233

  • 1. Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma.
    Newton DL, Hansen HJ, Mikulski SM, Goldenberg DM, Rybak SM.
    Blood; 2001 Jan 15; 97(2):528-35. PubMed ID: 11154233
    [Abstract] [Full Text] [Related]

  • 2. The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin.
    Ghetie MA, Tucker K, Richardson J, Uhr JW, Vitetta ES.
    Blood; 1992 Nov 01; 80(9):2315-20. PubMed ID: 1384801
    [Abstract] [Full Text] [Related]

  • 3. Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites.
    Ghetie MA, Richardson J, Tucker T, Jones D, Uhr JW, Vitetta ES.
    Cancer Res; 1991 Nov 01; 51(21):5876-80. PubMed ID: 1933855
    [Abstract] [Full Text] [Related]

  • 4. Highly potent CD22-recombinant ricin A results in complete cure of disseminated malignant B-cell xenografts in SCID mice but fails to cure solid xenografts in nude mice.
    Van Horssen PJ, Preijers FW, Van Oosterhout YV, De Witte T.
    Int J Cancer; 1996 Nov 04; 68(3):378-83. PubMed ID: 8903481
    [Abstract] [Full Text] [Related]

  • 5. Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents.
    Newton DL, Hansen HJ, Liu H, Ruby D, Iordanov MS, Magun BE, Goldenberg DM, Rybak SM.
    Crit Rev Oncol Hematol; 2001 Nov 04; 39(1-2):79-86. PubMed ID: 11418304
    [Abstract] [Full Text] [Related]

  • 6. Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22.
    Sharkey RM, Behr TM, Mattes MJ, Stein R, Griffiths GL, Shih LB, Hansen HJ, Blumenthal RD, Dunn RM, Juweid ME, Goldenberg DM.
    Cancer Immunol Immunother; 1997 May 04; 44(3):179-88. PubMed ID: 9191878
    [Abstract] [Full Text] [Related]

  • 7. Relationship of the CD22 immunotoxin dose and the tumour establishment in a SCID mice model.
    Van Horssen PJ, Preijers FW, Van Oosterhout YV, Eling WM, De Witte T.
    Leuk Lymphoma; 2000 Nov 04; 39(5-6):591-9. PubMed ID: 11342342
    [Abstract] [Full Text] [Related]

  • 8. Antibody targeted therapeutics for lymphoma: new focus on the CD22 antigen and RNA.
    Newton DL, Ryback SM.
    Expert Opin Biol Ther; 2001 Nov 04; 1(6):995-1003. PubMed ID: 11728231
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Evaluation of four CD22 antibodies as ricin A chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas.
    Shen GL, Li JL, Ghetie MA, Ghetie V, May RD, Till M, Brown AN, Relf M, Knowles P, Uhr JW.
    Int J Cancer; 1988 Nov 15; 42(5):792-7. PubMed ID: 3263328
    [Abstract] [Full Text] [Related]

  • 11. Eradication of minimal disease in severe combined immunodeficient mice with disseminated Daudi lymphoma using chemotherapy and an immunotoxin cocktail.
    Ghetie MA, Tucker K, Richardson J, Uhr JW, Vitetta ES.
    Blood; 1994 Aug 01; 84(3):702-7. PubMed ID: 7519071
    [Abstract] [Full Text] [Related]

  • 12. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody.
    Juweid M, Sharkey RM, Markowitz A, Behr T, Swayne LC, Dunn R, Hansen HJ, Shevitz J, Leung SO, Rubin AD.
    Cancer Res; 1995 Dec 01; 55(23 Suppl):5899s-5907s. PubMed ID: 7493367
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Phase I/II trial of multiple dose 131Iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin's lymphoma.
    Vose JM, Colcher D, Gobar L, Bierman PJ, Augustine S, Tempero M, Leichner P, Lynch JC, Goldenberg D, Armitage JO.
    Leuk Lymphoma; 2000 Jun 01; 38(1-2):91-101. PubMed ID: 10811451
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Delivery of the ribosome-inactivating protein, gelonin, to lymphoma cells via CD22 and CD38 using bispecific antibodies.
    French RR, Penney CA, Browning AC, Stirpe F, George AJ, Glennie MJ.
    Br J Cancer; 1995 May 01; 71(5):986-94. PubMed ID: 7734325
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.